Search Results for "Kinemed"
Original Source: KineMed Inc.
KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag⢠and KineMarkerâ¢) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. The Company is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstra...
Matching Channels
None
Matching News
Isis Pharmaceuticals in partnership with KineMed and CHDI Foundation
KineMed, Isis Pharmaceuticals , and CHDI Foundation are in partnership to utilize KineMed’s translational biomarker platform with Isis’ antisense therapeutic program for Huntington’s disease. Th...
Isis to use Huntington's biomarkers from KineMed, CHDI
Isis Pharmaceuticals Inc. (NASDAQ:ISIS) will use biomarkers from KineMed Inc. (Emeryville, Calif.) and the not-for-profit CHDI Foundation Inc. (New York, N.Y.) to develop an antisense therapeutic for...
KineMed wins $1.2m grant to advance brain-process biomarker research
The Michael J. Fox Foundation has extended funding for KineMed's brain-process biomarker research for Parkinson's disease (PD).
KineMed, GSK enter multi-year biomarker discovery partnership
KineMed, Inc. announced today a multi-year R&D collaboration with GlaxoSmithKline plc that will apply KineMed's proprietary biomarker discovery platform in therapeutic areas of interest to GSK.
KineMed Announces Biomarker Discovery Collaboration with GSK
KineMed, Inc. (www.kinemed.com) announced today a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) (LSE: GSK, NYSE: GSK) that will apply KineMed’s propriet...
Isis Pharmaceuticals, KineMed, CHDI Foundation Inc. deal
Research will utilize KineMed technology KineMed Inc. (www.kinemed.com) today announced an agreement with MedImmune, the global biologics research and development arm o...
Matching PubMed Articles
AIMS/HYPOTHESIS: The primary aim of this completed multicentre randomised, parallel, double-blind placebo-controlled study was to elucidate the mechanisms of glucose-lowering wit...
It is proposed that caloric restriction (CR) increases mitochondrial biogenesis. However, it is not clear why CR increases an energetically costly biosynthetic process. We hypothesized that 40% CR wou...
